Hexyl 5-ALA Ester PDT for Reduced Side Effects

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) and its derivatives often results in undesirable side effects such as pain, erythema, and other skin irritations, particularly when treating facial or neck areas, limiting its effectiveness and patient comfort.

Innovation Solution

A composition comprising 5-ALA ester in concentrations of 0.5 to 8% wt, combined with a light source having a fluence rate of 5 to 40 mW/cm², is used for PDT, minimizing side effects while maintaining therapeutic efficacy by modifying the photosensitizer composition and treatment procedure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high concentration of 5-ALA ester (e.g., 16% wt) is used in PDT treatment, then therapeutic efficacy is improved, but side effects (pain, erythema, swelling) worsen

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidside effects (pain, erythema)
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by reducing the concentration of 5-ALA ester from conventional high doses (16% wt) to lower doses (0.5-8% wt), and simultaneously adjusting the light fluence rate from high to moderate levels (5-40 mW/cm²). This dual parameter adjustment maintains therapeutic efficacy while significantly reducing side effects such as pain and erythema.

Inventive Principle:
Principle #35Parameter changes

2Loss of time

If high light fluence rate is used in PDT, then treatment duration is reduced, but side effects (pain, burning sensation) worsen

Engineering Contradiction:
Improvetreatment durationVSAvoidside effects (pain, burning)
Core Design Contradiction:
Loss of timeVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using moderate light fluence rates (5-40 mW/cm²) rather than high fluence rates, combined with lower photosensitizer concentrations. This partial dosing approach achieves sufficient therapeutic effect while avoiding excessive tissue stimulation that causes pain and burning sensations, thereby reducing side effects without completely sacrificing treatment efficiency.

Inventive Principle:
Principle #16Partial or excessive action

3Reliability

If conventional PDT regime (high dose, high energy) is used, then permanent improvement is achieved, but patient comfort and tolerability worsen

Engineering Contradiction:
Improvepermanent improvementVSAvoidpatient comfort
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent implements parameter changes by establishing a new treatment regime with 5-ALA ester concentrations of 0.5-8% wt and light fluence rates of 5-40 mW/cm². This modified parameter set delivers permanent therapeutic improvement comparable to conventional high-dose treatments while significantly enhancing patient comfort and tolerability, making the treatment more acceptable for facial and visible area applications.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves substantially pain-free and therapeutically acceptable PDT, with a high therapeutic effect similar to standard treatments, reducing side effects like pain and erythema, and allowing for effective treatment of conditions like acne without significant discomfort.

Implementation Method 1

PDT involves the application of photosensitizing (photochemotherapeutic) agents to the affected area of the body, followed by exposure to photoactivating light in order to activate the photosensitizing agents and convert them into cytotoxic form

Methodology Applied
Scientific EffectPhotodynamic therapy: Photo-oxidation

Data Source

PatentEP2754439B1Use of aminolevulinic acid derivatives
Publication Date: 2021.10.13 PHOTOCURE

AI summary

The invention provides a composition comprising hexyl 5-ALA ester, or a pharmaceutically acceptable salt thereof, for use in photodynamic therapy (PDT) on an animal for the treatment of viral infections on the lining of the vagina, uterine cervix, or uterus, wherein said PDT comprises: (a) administration of the composition to said animal; and (b) photoactivation of said hexyl 5-ALA ester, and wherein side-effects of said PDT are prevented or reduced by (i) said composition comprises said hexyl 5-ALA ester in a concentration of 0.5 to 6 % wt, and (ii) said photoactivation is carried out with a light source having a fluence rate of 5 to 40 mW/cm2.